Activation and expansion of T-cells using an engineered multivalent signaling platform
View Patent ↗The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.
1. An engineered multivalent signaling platform (EMSP) comprising a K562 cell line for use in long term expansion of T cells, wherein said K562 comprises on its surface: at least one molecule that is capable of stimulating a primary signal to the T cell, wherein said at least one molecule is an exogenous antibody that binds to CD2; a ligand for CD28, wherein said ligand for CD28 is capable of cross-linking CD28 on T cells and delivering a secondary signal to said T cells, wherein said ligand is selected from the group consisting of anti-CD28 antibody, CD80, and CD86; and wherein said EMSP is further genetically modified to express the co-stimulatory molecule, 4-1BBL.
2. The EMSP of claim 1 wherein said K562 cell line is a cell that is genetically modified to express a human Fcγ receptor.
3. The EMSP of claim 2 wherein said human Fcγ receptor comprises CD32.
4. The EMSP of claim 2 wherein said exogenous antibody is displayed on the surface of said K562 cell line via interaction with the Fcγ receptor.
5. The EMSP of claim 1 wherein said K562 cell line is a cell that has been modified to express a cytokine.
6. The EMSP of claim 5 wherein said cytokine is selected from the group consisting of IL-2, GM-CSF, IL-4, TNF-α, and IFN-γ.
7. The EMSP of claim 1 wherein said T cells comprise CD4 + T cells.
8. The EMSP of claim 1 wherein said T cells comprise CD8 + T cells.
9. The EMSP of claim 1 wherein said T cells comprise regulatory T cells.
10. The EMSP of claim 2 , wherein said anti-CD28 antibody is displayed on the surface of said K562 cell line via interaction with the Fcγ receptor.
11. The EMSP of claim 4 wherein said antibody is an anti-CD2 antibody.
12. The EMSP of claim 4 wherein said antibody comprises anti-CD2 and anti-CD28.
13. The EMSP of claim 1 , further comprising at least an antigen.
14. The EMSP of claim 13 wherein said antigen is selected from the group consisting of a tumor antigen, a bacterial antigen, a fungal antigen, a viral antigen, and an autoantigen.
15. The EMSP of claim 1 wherein said exogenous antibody is anti-CD2 antibody and said ligand for CD28 is anti-CD28 antibody, further wherein said EMSP induces T cells to remain in exponential growth after a third round of stimulation with said EMSP.